Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
1. Stable nanoparticles comprising cholesterol and saponin quillaja saponin fraction QHC from Quillaha saponaria Molina , wherein the nanoparticles do not comprise a phospholipid and have a particle diameter in the range of 17-20 nanometers wherein the molar ratio between cholesterol and quillaja saponin is from 1:2 to 2:1.
2. The nanoparticles according to claim 1 , further comprising at least one of an amphipathic or a hydrophobic molecule.
3. Nanoparticles according to claim 2 , wherein the amphipathic or hydrophobic molecule is at least one member selected from an antigen, an adjuvant, a targeting molecule, a pharmaceutical compound and a food related compound.
4. A composition comprising a first plurality of nanoparticles according to claim 1 and a second plurality of nanoparticles comprising cholesterol and a component from Quillaha saponaria Molina selected from quillaja acid and quillaja saponin, wherein the second plurality of nanoparticles do not comprise a phospholipid.
5. The composition according to claim 4 , wherein the first plurality of nanoparticles and the second plurality nanoparticles comprise different quillaja saponin fractions.
6. A pharmaceutical composition comprising nanoparticles according to claim 1 and further comprising pharmaceutically acceptable buffers, diluents excipients, adjuvants and/or carriers.
7. A composition according to claim 4 , further comprising pharmaceutically acceptable buffers, diluents excipients, adjuvants and/or carriers.
8. The composition according to claim 7 further comprising a vaccine.
9. Nanoparticles according to claim 3 , wherein the adjuvant is diterpene.
10. The pharmaceutical composition according to claim 6 , wherein the adjuvant is diterpene.
11. The pharmaceutical composition according to claim 6 , further comprising a vaccine.
12. The pharmaceutical composition according to claim 10 , wherein the vaccine is a pandemic flu vaccine.
13. The pharmaceutical composition according to claim 10 , wherein the vaccine is a seasonal influenza virus vaccine.
14. The pharmaceutical composition according to claim 10 , wherein the vaccine is a pandemic influenza virus vaccine.
15. The pharmaceutical composition according to claim 10 , wherein the vaccine is a vaccine against a biological weapon.
16. The pharmaceutical composition according to claim 6 , further comprising at least one of an anticancer drug Komplettering Saideh, a platinum coordination compound, a taxane compound, a camptohtecin compounds, an anti-tumor vinca alkaloid, an anti-tumor nucleoside derivative, a nitrogen mustard or nitrosourea alkylating agent, an anti-tumor anthracycline derivative, a trastzumab, an anti-tumor podophyllotoxon derivative, an antimetabolite, a steroid, an inhibitor of a mammalian target of rapamycin (mTOR), an agent for treating cancer, Cytarabin, Daunorubicin, Paclitaxel, Docetaxel, Cabazitaxel, Toricsel, and Trabectidin.
17. The nanoparticles according to claim 3 , wherein the amphipathic or hydrophobic molecule is an adjuvant.
18. The nanoparticles according to claim 17 , further comprising a vaccine.
19. The nanoparticles according to claim 3 , wherein the amphipathic or hydrophobic molecule is chosen from Diterpenoid (DT), VLX40, Busulfan, roscovitine and vitamin D3.